| S0178 |
GLX351322 |
GLX351322 is a NADPH oxidase 4 (NOX4) inhibitor. GLX351322 inhibits hydrogen peroxide production from tetracycline inducible NOX4-overexpressing cells with IC50 of 5 μM. |
Selective |
NOX4, IC50: 5 μM |
| S7171 |
Setanaxib (GKT137831) |
Setanaxib (GKT137831, GKT831) is a potent, dual NADPH oxidase NOX1/NOX4 inhibitor with Ki of 110 nM and 140 nM, respectively. Treatment with GKT137831 suppresses reactive oxygen species (ROS) production. GKT137831 partly inhibits ferroptosis. |
Pan |
NOX4, Ki: 140 nM |
| S0777 |
Isuzinaxib (APX-115 free base) |
Isuzinaxib (APX-115 free base, Ewha-18278 free base) is a potent, orally active inhibitor of pan NADPH oxidase (pan-Nox) with Ki of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. APX-115 free base (Ewha-18278 free base) significantly suppresses the expression of inflammatory molecules including MCP-1/CCL2, IL-6, and TNFα in the diabetic kidney. |
Pan |
NOX4, Ki: 0.63 μM |
| S5304 |
2-Acetylphenothiazine (ML171) |
2-Acetylphenothiazine (ML171, 2-APT) is a potent and selective inhibitor of NADPH-oxidase with IC50s of 0.25 μM, 5 μM, 3μM, 5 μM and 5.5 μM for NOX1, NOX2, NOX3, NOX4 and xanthine oxidase, respectively. |
Pan |
NOX4, IC50: 5 μM |
